Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Journal of acquired immune deficiency syndromes (1999) - 15 Aug 2001

Miller M D, Margot N A, Lamy P D, Fuller M D, Anton K E, Mulato A S, Cherrington J M

Abstract excerpt

OBJECTIVE: To determine whether genotypic changes in HIV-1 (HIV) reverse transcriptase (RT) occur during adefovir dipivoxil (ADV) therapy that may alter the susceptibility of HIV to adefovir or the related nucleotide inhibitor, tenofovir. DESIGN AND METHODS: GS-96-408 was a 1:1 randomized, double-blind, phase III clinical trial assessing the safety and efficacy of 120-mg daily ADV compared with placebo for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Viral

Share to HIV Reverse Transcriptase

Share to Organophosphonates

Share to Organophosphorus Compounds

Share to Reverse Transcriptase Inhibitors

Share to Tenofovir

Source

Identifiers

PMID: 11511821
DOI: 10.1097/00126334-200108150-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.PMID 11511821Read ↗

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Semantic proximity Read ↗

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.Semantic proximity Read ↗

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.Semantic proximity Read ↗

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.Semantic proximity Read ↗

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.Semantic proximity Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In VitroSemantic proximity Read ↗

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.Semantic proximity Read ↗

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.